Rank |
Status |
Study |
1 |
Recruiting
|
MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction
Condition: |
Migraine |
Interventions: |
Device: MRI; Device: EndoPAT; Other: Neuropsychological battery |
Outcome Measures: |
Differences in magnetic resonance imaging (MRI) between Migraine without aura and Migraine with aura patients (frequency of hyperintensities, white matter lesions....); Differences in the Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) between Migraine without aura and Migraine with aura patients.; Differences in the Reactive Hyperemia Index (RHI) and the Augmentation Index (AI) between Migraine without aura and Migraine with aura patients; Correlation between MRI and Total Score of RBANS with RHI / AI (endothelial function) between Migraine groups. |
|
2 |
Recruiting
|
Behavioral Weight Loss as a Treatment for Migraine in Obese Women
Conditions: |
Migraine; Obesity |
Interventions: |
Behavioral: Behavioral Weight Loss Intervention; Other: Migraine Education |
Outcome Measures: |
Change in the number of Migraine headache days; Change in body weight; Changes in serum inflammatory markers (C-reactive protein, Interleukin-6); Changes in depression; Changes in physical activity; Changes in fat intake and other diet/eating behavior components |
|
3 |
Recruiting
|
One-Day Intervention for Depression and Impairment in Migraine Patients
Conditions: |
Migraine; Depression |
Interventions: |
Behavioral: ACT-ME; Behavioral: Migraine Education Only |
Outcome Measures: |
HRSD; SCID-IV; WHO-DAS-II; WHO-QOL; HDI |
|
4 |
Unknown †
|
Identification of Inflammatory Markers in Migraine Patients
Conditions: |
Inflammation; Migraine; Headache |
Intervention: |
|
Outcome Measures: |
To evaluate if the levels of inflammatory markers in patients with Migraine is higher compared to the levels of these markers in the control groups.; To evaluate the levels of inflammatory markers in-between Migraine and other forms of headaches. |
|
5 |
Recruiting
|
Migraine and Body Composition
Conditions: |
Migraine With and Without Aura; Chronic Migraine; Healthy Controls |
Intervention: |
|
Outcome Measures: |
association between Migraine and obesity - evaluate serum adipokine levels; association between Migraine and obesity -evaluate subcutaneous adipose tissue (SAT) and its ratio to visceral adipose tissue (VAT) |
|
6 |
Unknown †
|
Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents
Condition: |
Migraine |
Intervention: |
Dietary Supplement: Migra 3 |
Outcome Measures: |
number of days with headache before and after 12 weeks of daily treatment with a Migraine specific dietary supplement; frequency, duration and intensity of the Migraine |
|
7 |
Unknown †
|
Treximet in Acute Migraine Headache: Assessing Cognitive Function
Conditions: |
Migraine Headache; Cognitive Impairment |
Interventions: |
Drug: Treximet; Drug: Migraine rescue medication of choice |
Outcome Measures: |
To evaluate the effectiveness of treatment with Treximet versus placebo in patients with acute Migraine headache on the neuropsychological function before treatment and at one and two hours after treatment of a Migraine.; To assess incidence and types of neuropsychological deficits by MEWT in patients with acute Migraine headache before treatment. |
|
8 |
Recruiting
|
The Childhood and Adolescent Migraine Prevention Study
Conditions: |
Migraine; Migraine Disorders; Headache |
Interventions: |
Drug: Amitriptyline; Drug: Topiramate; Drug: Placebo |
Outcome Measures: |
Reduction in Migraine Frequency (amitriptyline and topiramate); Reduction in absolute Migraine disability score on PedMIDAS; Safety and tolerability of amitriptyline and topiramate; Occurrence of treatment-emergent serious adverse events; Reduction in absolute Migraine frequency days |
|
9 |
Recruiting
|
Acupuncture for Migraine Prophylaxis
Conditions: |
Migraine Without Aura; Unilateral Headache |
Intervention: |
Other: acupuncture |
Outcome Measures: |
frequency of Migraine attacks; headache severity |
|
10 |
Recruiting
|
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Condition: |
Migraine Headache, Episodic |
Intervention: |
Device: neuromodulation for episodic Migraine headache |
Outcome Measures: |
Number of monthly Migraine headache days; Number of monthly Migraine headache days (reduction by by 50% or more); Total monthly pain score; Mood and cognition measures - Change in mood scores; Verify the absence of material dizziness; Mood and cognition measures - Change in cognitive speed scores; Mood and cognition measures - Change in memory scores |
|
11 |
Not yet recruiting
|
Prediction of Migraine Prevention Efficacy: Individualization of Treatment by Coupling Drug's Mode of Action With Patient's Mechanism of Pain Modulation
Conditions: |
Migraine; Preventive Treatment |
Interventions: |
Drug: Amitriptyline; Drug: placebo |
Outcome Measures: |
the association between pre-treatment assessment parameter(s) and the reduction in frequency of Migraine attacks by amitriptyline; the association between pain-related psychological parameters and the reduction in Migraine attacks by amitriptyline |
|
12 |
Recruiting
|
A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine
Condition: |
Migraine According to International Headache Society (IHS) Criteria (ICHD-II) |
Interventions: |
Drug: D3 Vitamin ®; Drug: Placebo |
Outcome Measures: |
The number of Migraine attacks; Evaluation of pain during Migraine attacks; Hypersensitivity; Migraine Symptoms; Quantitative Sensory Testing; Measuring levels of a biomarker. Changes in the levels of these biomarkers. |
|
13 |
Recruiting
|
Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
Condition: |
Workplace Migraine Treatment |
Interventions: |
Drug: Usual prescribed triptan; Drug: Treximet for Migraine treatment |
Outcome Measures: |
workplace productivity compared between Migraines treated with usual triptan versus Migraines treated with Treximet; comparison of patient completeness of response to Migraine treatments across 6 treated workplace Migraines |
|
14 |
Recruiting
|
TI-001 (Intranasal Oxytocin) for Treatment of Chronic Migraine
Condition: |
Chronic Migraine |
Interventions: |
Drug: TI-001; Drug: Placebo |
Outcome Measures: |
Mean reduction in Migraine headache days; Change in Migraine pain scores measured with a 4-point verbal rating scale; Frequency of nausea; Frequency of photophobia; Frequency of phonophobia; Frequency of Migraine episodes; Time to study discontinuation due to any cause; Frequency and severity of adverse events |
|
15 |
Recruiting
|
Pathway M-1: Sphenopalatine Ganglion Stimulation for the Treatment of Chronic or High Frequency, High Disability Migraine Headache
Conditions: |
Chronic Migraine; High Frequency, High Disability Migraine |
Intervention: |
Device: ATI Neurostimulation System |
Outcome Measures: |
Major Device- and Surgical-Related Complications; Effective Therapy; Headache Frequency; Pain Relief at 1 Hour; Pain Freedom at 1 Hour; Migraine Associated Symptom Relief at 1 Hour; Disability and Quality of Life; Global Evaluation of SPG Stimulation Therapy; Prophylactic Medication Use; Acute Medication Use |
|
16 |
Unknown †
|
Inflammatory Markers Identification in Migraine Patients
Conditions: |
Inflammation; Migraine; Headache |
Intervention: |
|
Outcome Measure: |
|
|
17 |
Unknown †
|
The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine
Conditions: |
Migraine Disorders; Migraine Headache; Migraine; Acute Migraine |
Interventions: |
Drug: Topical, intra-oral ketoprofen gel; Other: Placebo gel |
Outcome Measures: |
Pain relief (defined as at least 2 graded reduction in a 5-grade scale) at 120 minutes post-treatment; Pain free status at 30, 60, 120, and 240 minutes post-treatment based on headache severities reported in patient's journals; Pain relief at 30, 60, and 240 minutes post-treatment based on headache severities reported in patient's journals; Relief of Photophobia at 30, 60, 120, and 240 minutes post-treatment; Relief of Phonophobia at 30, 60, 120, and 240 minutes post-treatment; Relief of Nausea at 30, 60, 120 and 240 minutes post-treatment; Relief of Vomiting 30, 60, 120 and 240 minutes post-treatment; Need for Rescue Medication between the time of dosing to 240 minutes |
|
18 |
Recruiting
|
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load
Condition: |
Migraine Without Aura |
Intervention: |
Drug: PACAP |
Outcome Measures: |
PACAP induced Migraine attacks in patients with high and low genetic load.; PACAP induced Migraine attacks in patients with high and low genetic load |
|
19 |
Recruiting
|
Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects
Condition: |
Migraine |
Intervention: |
Drug: Clopidogrel |
Outcome Measures: |
Mean number of monthly Migraine days per patient within the 3 months following transcatheter ASD closure.; Severity of Migraine attacks following ASD closure as evaluated by the intensity of Migraine episodes and the Migraine Disability Assessment (MIDAS) questionnaire at 3-month follow-up after ASD closure.; Incidence of bleeding complications at 3-month follow-up.; Percentage of patients with new-onset Migraine attacks.; Time to first Migraine episode.; Percentage of patients with Migraine headaches at 6-month and 1-year follow-up (exploratory only according to local feasibility). |
|
20 |
Recruiting
|
A Randomized, Placebo-Controlled, Double-blind Study of Tianshu Capsule in the Treatment of Migraine.
Condition: |
Migraine |
Interventions: |
Drug: Tianshu capsule; Drug: Sugar pill |
Outcome Measures: |
Change in the frequency of attack of Migraine Per 4 weeks at Week 16 from baseline; Change in seizure duration of Migraine Per 4 weeks at Week 16 from baseline.; Change in degree of pain of Migraine Per 4 weeks at Week 16 from baseline.; Change in the days using acute therapy of Migraine Per 4 weeks at Week 16 from baseline.; Proportion of subjects whose number or days of Migraine attacks reduce at least 50%.; Change in number of concomitant migrainous symptoms attacks Per 4 weeks at Week 16 from baseline.; Safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiogram, and clinical laboratory tests. |
|